Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.A. Austin, J.E. Hokanson, K.L. Edwards.
Hypertriglyceridemia as a cardiovascular risk factor.
Am J Cardiol, 78 (1998), pp. 7-13
[2.]
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III).
JAMA, 285 (2001), pp. 2486-2496
[3.]
B. Lamarche, P.J. Després, S. Moorjani, B. Cantin, G.R. Dagenais, J.P. Lupien.
Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study.
Am J Cardiol, 75 (1995), pp. 1189-1195
[4.]
H.T. Westerveld, J.E. Roeters van Lennep, H.W. Roeters van Lennep, A.H. Liem, J.A. Boo, Y.T. Schouw, et al.
Apolipoprotein B and coronay artery disease in women.
Arterioscler Thromb Vasc Biol, 18 (1998), pp. 1101-1107
[5.]
J.E. Roeters van Lennep, H.T. Westerveld, H.W. Roeters van Lennep, A.H. Zwinderman, D.W. Erkelens, E.E. van Der Wall.
Apolipoprotein concentrations during treatment and recurrent coronary artery disease events.
Arterioscler Thromb Vasc Biol, 20 (2000), pp. 2408-2413
[6.]
A.M. Gotto, E. Whitney, E.A. Stein, D.R. Shapiro, M. Clearfield, S. Weis, et al.
Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS.
Circulation, 101 (2000), pp. 477-484
[7.]
G. Walldius, I. Jungner, I. Holme, A.H. Aastveit, W. Kolar, E. Steiner.
High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.
Lancet, 358 (2001), pp. 2026-2033
[8.]
J. Ortolá, M.J. Castineiras, X. Fuentes-Arderiu.
Biological variation data applied to the selection of serum lipid ratios used as risk markers of coronary heart disease.
Clin Chem, 38 (1992), pp. 56-59
[9.]
Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
N Engl J Med, 339 (1998), pp. 1349-1357
[10.]
F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.C. Rutherford, T.G. Cole, et al.
for the Cholesterol Recurrent Events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
N Engl J Med, 335 (1996), pp. 1001-1009
[11.]
T.R. Pedersen, A.G. Olsson, O. Faergeman, J. Kjekshus, H. Wedel, K. Berg, et al.
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Atudy (4S.
Circulation, 97 (1998), pp. 1453-1460
[12.]
A.M. Wägner, A. Pérez, F. Calvo, R. Bonet, A. Castellví, J. Ordóñez.
Apolipoprotein B identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients.
Diabetes Care, 22 (1999), pp. 812-817
[13.]
A.M. Wägner, A. Pérez, F. Blanco-Vaca, M. Rigla, M. Cortés, J.L. Sánchez-Quesada, et al.
Inaccuracy of calculated LDL cholesterol in type 2 diabetes: consequences for patient risk classification and therapeutic decision.
Clin Chem, 46 (2000), pp. 1830-1832
[14.]
T. Planella, M. Cortés, C. Martínez-Brú, F. González-Sastre, J. Ordóñez-Llanos.
Calculation of LDL cholesterol using apolipoprotein B for the phenotypical classification of non-chylomicronæmic dyslipæmia.
Clin Chem, 43 (1997), pp. 808-815
[15.]
B. Lamarche, A. Tchernof, S. Moorjani, B. Cantin, G.R. Dagenais, P.J. Lupien, et al.
Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men.
Circulation, 95 (1997), pp. 69-75
[16.]
B.F. Stewart, B.G. Brown, X.Q. Zhao, L.A. Hillger, A.D. Sniderman, A. Dowdy, et al.
Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.
J Am Coll Cardiol, 23 (1994), pp. 899-906
[17.]
P.O. Kwiterovich, J. Coresh, P.S. Bachorik.
Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged ≤ 50 years) and women (≤ 60 years) with coronary artery disease.
Am J Cardiol, 71 (1993), pp. 631-639
[18.]
A.D. Sniderman, X.J. Zhang, K. Cianflone.
Governance of the concentrations of plasma LDL: a reevaluation of the LDL receptor paradigm.
Atherosclerosis, 148 (1999), pp. 215-229
[19.]
S.M. Marcovina, J.J. Albers, H. Kennedy, J.V. Mei, L.O. Henderson, W.H. Hannon.
International Federation of Clinical Chemistry standardization project for measurement of apolipoproteins A-I and B.Comparability of apolipoprotein B values by use of International Reference Material.
Clin Chem, 40 (1994), pp. 586-592
[20.]
I. Jungner, S.M. Marcovina, G. Walldius, I. Holme, W. Kolar, E. Steiner.
Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials.
Clin Chem, 44 (1998), pp. 1641-1649
[21.]
P.S. Bachorik, K.L. Lovejoy, M.D. Carroll, C.L. Johnson.
Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III.
Clin Chem, 43 (1997), pp. 2364-2378
Copyright © 2002. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.